Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories
At least two experimental COVID-19 vaccines produced a T-cell response in participants in early-stage clinical trials, which may indicate a more durable form of immunity than an antibody response.